Form 4: Altimmune CBO Buys Shares via ESPP

Altimmune's Chief Business Officer, Raymond M. Jordt, acquired 1,368 shares of common stock through the company's Employee Stock Purchase Plan.

Summary

• Raymond M. Jordt, Chief Business Officer of Altimmune, Inc., acquired 1,368 shares of Altimmune common stock.
• The shares were purchased at a price of $3.14 per share.
• This transaction occurred on July 31, 2025, as part of the company's 2019 Employee Stock Purchase Plan (ESPP).
• The purchase price reflects 85% of the closing price of Altimmune's common stock on July 31, 2025.
• Following this transaction, Raymond M. Jordt beneficially owns 36,270 shares of Altimmune common stock directly.
• The ESPP purchase period for these shares was from February 1, 2025, through July 31, 2025.

Sentiment

Score: 7

Explanation: The acquisition of shares by a Chief Business Officer, even through an ESPP, generally indicates positive sentiment and confidence in the company's future prospects from an insider's perspective.

Positives

• A company officer, the Chief Business Officer, purchased shares, indicating confidence in the company's future prospects.
• The purchase was made through an Employee Stock Purchase Plan (ESPP), which often allows employees to acquire shares at a discount, demonstrating a commitment to employee ownership.

Future Outlook

NA

Industry Context

This transaction is an internal personnel-related disclosure and does not directly reflect broader industry trends. However, insider purchases, even through an ESPP, can be viewed as a positive signal of management's belief in the company's value within the biotechnology sector.

Related Party Transactions

• The transaction involves the purchase of shares by a company officer through the company's Employee Stock Purchase Plan (ESPP), which is a common form of related-party transaction designed to align employee and shareholder interests.

Stakeholder Impact

• Shareholders: The insider purchase may be viewed positively, signaling management's confidence and potentially increasing investor trust.
• Employees: The Employee Stock Purchase Plan (ESPP) encourages employee ownership, aligning employee interests with company performance.

Key Dates

Recommendation

While the insider purchase is a positive signal, a single ESPP transaction by an officer, even at a discount, is not typically a strong enough catalyst on its own to warrant a 'buy' recommendation without further fundamental analysis of Altimmune's broader financial health, pipeline, and market position. It reinforces a 'hold' position for existing investors and suggests continued monitoring for potential investors.

Keywords

Altimmune, ALT, SEC Form 4, Insider Trading, Stock Purchase, Employee Stock Purchase Plan, ESPP, Chief Business Officer, Raymond M. Jordt, Biotechnology, Pharmaceuticals